Global Lung Cancer Therapeutics Market Overview:
Global Lung Cancer Therapeutics Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2025-2032, Considering the Base Year As 2024.
Global Lung Cancer Therapeutics Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Lung Cancer Therapeutics involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Lung Cancer Therapeutics Market:
The Lung Cancer Therapeutics Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Lung Cancer Therapeutics Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Lung Cancer Therapeutics Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Lung Cancer Therapeutics market has been segmented into:
Non-Small-Cell Lung Cancer (NSCLC)
Small-Cell Lung Cancer (SCLC)).
By Application, Lung Cancer Therapeutics market has been segmented into:
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Lung Cancer Therapeutics market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Lung Cancer Therapeutics market.
Top Key Players Covered in Lung Cancer Therapeutics market are:
AEterna Zentaris Inc.
Agennix AG
American Lung Association
Arcus Biosciences
Avid Bioservices Inc.
BIND Therapeutics Inc.
Bristol-Myers Squibb Company
Centrose
LLC.
Cipla Europe NV
Co-D Therapeutics
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Lung Cancer Therapeutics Market Type
4.1 Lung Cancer Therapeutics Market Snapshot and Growth Engine
4.2 Lung Cancer Therapeutics Market Overview
4.3 Non-Small-Cell Lung Cancer (NSCLC)
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Non-Small-Cell Lung Cancer (NSCLC): Geographic Segmentation Analysis
4.4 Small-Cell Lung Cancer (SCLC)).
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Small-Cell Lung Cancer (SCLC)).: Geographic Segmentation Analysis
Chapter 5: Lung Cancer Therapeutics Market Application
5.1 Lung Cancer Therapeutics Market Snapshot and Growth Engine
5.2 Lung Cancer Therapeutics Market Overview
5.3
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 : Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Lung Cancer Therapeutics Market Share by Manufacturer (2025)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 AETERNA ZENTARIS
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 INC.; AGENNIX AG; AMERICAN LUNG ASSOCIATION; ARCUS BIOSCIENCES; AVID BIOSERVICES
6.4 INC.; BIND THERAPEUTICS
6.5 INC.; BRISTOL-MYERS SQUIBB COMPANY; CENTROSE
6.6 LLC.; CIPLA EUROPE NV; CO-D THERAPEUTICS
Chapter 7: Global Lung Cancer Therapeutics Market By Region
7.1 Overview
7.2. North America Lung Cancer Therapeutics Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Non-Small-Cell Lung Cancer (NSCLC)
7.2.2.2 Small-Cell Lung Cancer (SCLC)).
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Lung Cancer Therapeutics Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Non-Small-Cell Lung Cancer (NSCLC)
7.3.2.2 Small-Cell Lung Cancer (SCLC)).
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Lung Cancer Therapeutics Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Non-Small-Cell Lung Cancer (NSCLC)
7.4.2.2 Small-Cell Lung Cancer (SCLC)).
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Lung Cancer Therapeutics Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Non-Small-Cell Lung Cancer (NSCLC)
7.5.2.2 Small-Cell Lung Cancer (SCLC)).
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Lung Cancer Therapeutics Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Non-Small-Cell Lung Cancer (NSCLC)
7.6.2.2 Small-Cell Lung Cancer (SCLC)).
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Lung Cancer Therapeutics Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Non-Small-Cell Lung Cancer (NSCLC)
7.7.2.2 Small-Cell Lung Cancer (SCLC)).
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Lung Cancer Therapeutics Scope:
|
Report Data
|
Lung Cancer Therapeutics Market
|
|
Lung Cancer Therapeutics Market Size in 2025
|
USD XX million
|
|
Lung Cancer Therapeutics CAGR 2025 - 2032
|
XX%
|
|
Lung Cancer Therapeutics Base Year
|
2024
|
|
Lung Cancer Therapeutics Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
AEterna Zentaris Inc., Agennix AG, American Lung Association, Arcus Biosciences, Avid Bioservices Inc., BIND Therapeutics Inc., Bristol-Myers Squibb Company, Centrose, LLC., Cipla Europe NV, Co-D Therapeutics.
|
|
Key Segments
|
By Type
Non-Small-Cell Lung Cancer (NSCLC)
Small-Cell Lung Cancer (SCLC)).
By Applications
|
